Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Language
Document Type
Year range
1.
East Asian Arch Psychiatry ; 32(1): 5-10, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1766172

ABSTRACT

OBJECTIVES: This study aims to examine the rates of anxiety, depression, and posttraumatic stress disorder (PTSD) after hospital discharge among COVID-19 survivors and to determine the associated risk factors. METHODS: Adult COVID-19 survivors discharged from hospitals between March 2020 and March 2021 were asked to complete a questionnaire at 4 weeks after discharge. The Chinese version of the 22-item Impact of Event Scale - Revised (IES-R) was used to measure symptoms of PTSD. The 9-item Patient Health Questionnaire (PHQ-9) was used to assess symptoms of major depressive disorder. The 7-item Generalised Anxiety Disorder Scale (GAD-7) was used to measure symptoms of generalised anxiety disorder. The rates of anxiety, depression, and PTSD among discharged patients were determined, as were associations between psychosocial factors and outcome measures and predictors for moderate-tosevere symptoms of anxiety, depression, and PTSD. RESULTS: 96 men and 103 women aged 18 to 81 years returned the completed questionnaire. 12.1% to 20.1% of them reported symptoms of PTSD, anxiety, or depression. Higher symptom severity was associated with higher perceived life threat, lower emotional support, lower disease severity upon admission, and longer hospital stay. Women had more PTSD symptoms than men, particularly when knowing someone under quarantine. CONCLUSION: COVID-19 survivors with higher perceived life threat, lower emotional support, lower disease severity upon admission, and longer hospital stay were associated with higher severity of symptoms of PTSD, anxiety, and depression. Timely intervention should provide to at-risk survivors.


Subject(s)
COVID-19 , Depressive Disorder, Major , Stress Disorders, Post-Traumatic , Adolescent , Adult , Aged , Aged, 80 and over , Anxiety/epidemiology , Anxiety Disorders/complications , Anxiety Disorders/epidemiology , COVID-19/epidemiology , Depression/epidemiology , Depressive Disorder, Major/complications , Female , Humans , Male , Middle Aged , Stress Disorders, Post-Traumatic/etiology , Survivors , Young Adult
2.
Hepatology ; 74(SUPPL 1):341A-342A, 2021.
Article in English | EMBASE | ID: covidwho-1508738

ABSTRACT

Background: The COVID19 pandemic has affected persons dietary habits and life style, with effects on body weight. We have assessed the effect of the pandemic on the liver health by quantifying the changes in liver enzymes, hepatic steatosis and fibrosis in patients with chronic liver disease. Methods: This is a multi-center US study that included 3 tertiary clinical centers. Patients with chronic liver disease (51 NAFLD, 8 with resolved hepatitis C, 3 chronic hepatitis B, 5 primary biliary cholangitis and 36 combination of chronic liver disease), without evidence of an acute process (e.g. alcoholic hepatitis, alcohol abuse or new decompensation of cirrhosis), were enrolled. Patients were assessed between January and March 2020 and January and March 2021. Assessment included laboratory tests and controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) on vibration transient elastography (VCTE). Results: 103 patients were assessed twice during the two periods. Baseline mean alanine aminotransferase (ALT) was 37 ± 36 (SD) U/L;aspartate aminotransferase (AST) 30 ± 18 U/L;total bilirubin 0.6 ± 0.31 mg/dL;albumin, 4.2 ± 0.72 g/dL;CAP score 293 ± 70 dB/m;and LSM on VCTE 8.1 ±6.2 kPa. Weight gain occurred in 54% of the population, whereas 39% lost weight, and 7% had no weight change. LSM increased by >20% in 30% of subjects;decreased by 20% in 27%;and remained within the 20% range in 43%. LSM increase by 20% was associated with significant weight gain and ALT increase (+2.3 ± 6.5 kg, and +17 ± 49.U/L (p<0.05)), in comparison to subjects who had their LSM changes within 20% range (+1.1 (3.7) kg, and -5.3 ±22.0 U/L) or had >20% decrease in LSM (-0.3 ±5.8 kg, and -6.0 ±21 U/L). CAP score median change was -2.9 ±85 dB/m in those who had LSM increase by >20%, whereas the score changed by 0.0 ± 44 dB/m in those who had LSM changes within 20% or 1.0 ± 58 dB/m in those >20% decrease. Conclusion: During the COVID 19 pandemic in this U.S. population, more than half of subjects with chronic liver disease gained weight, but others had no change or decreased weight. Adverse liver changes (LSM>20% and increased ALT) occurred in one-third of the population.

SELECTION OF CITATIONS
SEARCH DETAIL